Growth stocks are back in focus this month as investors look for companies with strong momentum and improving fundamentals. With Wall Street raising estimates across several high-growth names, a few stand out for offering more than 10% upside from current levels. Three top picks for May 2026 are Palo Alto Networks (PANW), Tarsus Pharmaceuticals (TARS), and Netflix (NFLX).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
One way to identify these stocks is through their past revenue or earnings growth. Today, we have shortlisted stocks whose revenue has grown at a five-year CAGR of more than 5%. Along with this, we have zeroed in on stocks that have received a “Strong Buy” rating from Wall Street analysts.
Here are this week’s stocks:
Palo Alto Networks (PANW) – This cybersecurity firm provides advanced network, cloud, and AI-driven security solutions to protect organizations from evolving digital threats. PANW stock’s average price target of $211.35 implies a 14.12% upside potential from the current level. The company’s revenue has grown at a five-year CAGR of 16.7%.
Importantly, TipRanks AI Analyst expects PANW’s revenue to grow by 15.43%, compared with the Technology sector’s average of 8.5%. Palo Alto Networks’ revenue growth is driven by strong demand for its AI‑powered security platform, rising adoption of next‑gen products, and expansion across large enterprise customers.
Tarsus Pharmaceuticals (TARS) – This commercial-stage biotech firm develops treatments for eye diseases, led by its flagship drug XDEMVY. TARS stock’s average price target of $88.78 implies an upside potential of 39.54%. Its revenue increased at a CAGR of 51.26% in the past five years.
According to TipRanks AI Analyst, TARS’ revenue is expected to grow by 146.71% in comparison to the Healthcare sector’s average of 22.53%. The company’s revenue growth is aided by expanding adoption of XDEMVY, rising prescriber demand, and a growing patient base in eye-care practices.
Netflix (NFLX) – This global streaming giant produces and distributes movies, series, and original content to millions of subscribers globally. NFLX stock’s average price target of $116.06 implies an upside potential of 27.16%. The company’s revenue has grown at a five-year CAGR of 8.75%.
The company’s revenue is expected to rise by 18.57%, according to TipRanks AI Analyst. This compares favorably with the Communication Services sector’s average of 2.83%. NFLX’s revenue growth is backed by steady subscriber gains, rising ad‑tier adoption, and benefits from recent price increases.